CANADA: Nanaimo based medical cannabis producer Tilray has partnered with the University of British Columbia Okanagan in Canada’s first clinical trial to test marijuana’s effectiveness in treating post-traumatic stress disorder.
The study, still waiting for approval from Health Canada, will be one of the world’s first large-scale clinical trials to evaluate cannabis for treating a mental health disorder.
Existing studies of marijuana’s affect on PTSD have produced anecdotal and observational data, but no information is available from science-based clinical trials. Scientifically generated results could provide physicians with data to make decisions about prescribing cannabis for PTSD patients.
Philippe Lucas, vice-president for patient research and services at Tilray, said a similar study in the U.S. is waiting final approval and funding, but results from both research programs should compliment one anther.